FDA panel reviews 1st new Alzheimer's drug in 2 decades
WASHINGTON (AP) — One of the biggest drug decisions in decades is looming as U.S. regulators consider whether to approve the first medicine that's claimed to slow mental decline from Alzheimer's disease, the most common form of dementia.
Become a Subscriber!
You have read all of your free articles this month. Select a plan below to start your subscription today.
Already a subscriber? Login
